Cancer Chemotherapy and Pharmacology

, Volume 59, Issue 1, pp 149–150 | Cite as

Negative results of an Italian Group for Mesothelioma (G.I.Me.) pilot study of single-agent imatinib mesylate in malignant pleural mesothelioma

Letter to the Editor

References

  1. 1.
    Vogelzang NJ, Porta C, Mutti L (2005) New agents in the management of malignant mesothelioma. Semin Oncol 32:336–350PubMedCrossRefGoogle Scholar
  2. 2.
    Butnor KJ, Burchette JL, Sporn TA, Hammar SP, Roggli VL (2004) The spectrum of Kit (CD117) immunoreactivity in lung and pleural tumors: a study of 96 cases using single-source antibody with a review of the literature Arch Pathol Lab Med 128:538–543PubMedGoogle Scholar
  3. 3.
    Catalano A, Rodilossi S, Rippo MR, Caprari P, Procopio A (2004) Induction of stem cell factor/C-kit/slug signal transduction in multidrug-resistant malignant mesothelioma cells J Biol Chem 279:46706–46714PubMedCrossRefGoogle Scholar
  4. 4.
    Villano JL, Husain AN, Stadler WM, Hanson LL, Vogelzang NJ, Kindler HL (2004) A phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM). Abs Am Assoc Clin Oncol 23:663 (abs. 7200)Google Scholar
  5. 5.
    Mathy A, Baas P, Dalesio O, van Zandwijk N (2005) Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial Lung Cancer 50:83–86PubMedCrossRefGoogle Scholar
  6. 6.
    Cacciotti P, Barbone D, Porta C, Mutti L, Gaudino G (2004) STI571 and gemcitabine combined cell treatment as a novel approach to malignant mesothelioma therapy. Abs. VII meeting of the International Mesothelioma Interest Group (IMIG), p 99Google Scholar

Copyright information

© Springer-Verlag 2006

Authors and Affiliations

  • Camillo Porta
    • 1
  • Luciano Mutti
    • 2
  • Gianfranco Tassi
    • 3
  1. 1.Medical OncologyI.R.C.C.S. San Matteo University HospitalPaviaItaly
  2. 2.Local Health Authority 11PiedmontItaly
  3. 3.PneumologyCivic HospitalBresciaItaly

Personalised recommendations